abstract |
(57) [Summary]nThe present invention relates to a method of treating a hematological malignancy associated with a large number of circulating tumor cells by administering a therapeutic chimeric anti-CD20 antibody. These malignancies include B-prolymphocytic leukemia (B-PLL), chronic lymphocytic leukemia (CLL), and transformed non-Hodgkin's lymphoma, among others. |